MedPath

Image-based Multi-scale Modeling Framework of the Cardiopulmonary System: Longitudinal Calibration and Assessment of Therapies in Pediatric Pulmonary Hypertension

Completed
Conditions
Congenital Heart Disease
Pulmonary Hypertension
Pediatric Congenital Heart Disease
Interventions
Procedure: cardiac catheterization
Radiation: Cardiac MRI
Registration Number
NCT03564522
Lead Sponsor
University of Michigan
Brief Summary

This study looks to develop a multi-scale computational model of Pulmonary Hypertension, this clinical model will be calibrated using longitudinal, retrospectively and prospectively acquired human clinical data.

Detailed Description

Pulmonary hypertension (PH) is a complex disorder associated with elevated pulmonary arterial pressure. Unlike systemic hypertension, PH is difficult to detect in routine physical examinations and the current gold standard for diagnosing PH is through invasive right heart catheterization. Prolonged PH results in functional, structural and anatomical changes in the right ventricle (RV), large pulmonary arteries, and the pulmonary micro-circulation that ultimately lead to decompensated RV failure and death. Unlike in systemic hypertension, for which patients have effective pharmacological management of blood pressure for decades, PH prognosis remains poor with 15% mortality within 1 year on modern therapy. Our current understanding of PH has largely been obtained through animal models and clinical studies. However, surgical banding or chronic hypoxia animal models do not fully reproduce the etiology of human PH, whereas invasive clinical measurements of pulmonary vascular resistance (PVR), stiffness and ventricular elastance provide limited insight into disease progression. Therefore, there is a pressing need to develop a multi-scale (MS) computational model that can couple the short term (e.g. hemodynamics) and long-term G\&R interactions between the RV and the pulmonary circulation.

The overall goals of this project are to use the framework to (1) describe the time course of the biomechanical alterations and (2) identify the key mechanical culprits associated with PH-induced heart failure so that clinical interventions can be targeted against them.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
35
Inclusion Criteria
  • Patients has been clinically diagnosed with pulmonary hypertension (>25 mmHg) or patient is a biopsy-proven non-rejecting cardiac transplant recipient
  • Receiving partial or full care from pediatric cardiology team at Mott Children's Hospital (may have a primary cardiologist elsewhere).
Read More
Exclusion Criteria
  • Girls and women who are pregnant or actively trying to become pregnant
  • Patients with significant neurocognitive impairment that precludes their ability to sign a consent form
  • Patient has a contraindication to right-heart catheterization (RHC) examination, which includes patients with hypoxia and those who have difficulty maintaining supine position for the procedure.
  • Patients with the following genetic syndromes:Trisomy 21 if unable to assent or consent, Trisomy 18,Trisomy 13, Other genetic syndromes at the discretion of the Primary Investigator
  • Patients with unrepaired single ventricles (i.e., Pre-Fontan physiology)
  • Patients who have heart failure and are deemed to be high risk to undergo tests that require sedation/anesthesia.
  • Patients who require IV sedation or general anesthesia for research only MRI
  • Patients with a pacemaker/internal defibrillator will be excluded from MRI PORTION ONLY
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Pulmonary HypertensionCardiac MRIParticipants diagnosed with pulmonary hypertension that will undergo a clinically indicated cardiac catheterization and cMRI.
Heart TransplantCardiac MRISuccessful cardiac transplant recipient without evidence of pulmonary hypertension, that will undergo clinically indicated cardiac catheterization.
Pulmonary Hypertensioncardiac catheterizationParticipants diagnosed with pulmonary hypertension that will undergo a clinically indicated cardiac catheterization and cMRI.
Heart Transplantcardiac catheterizationSuccessful cardiac transplant recipient without evidence of pulmonary hypertension, that will undergo clinically indicated cardiac catheterization.
Primary Outcome Measures
NameTimeMethod
3D volumetric data (mL/m2)1 hour

Modeling framework will be validated using 3D volumetric data (mL/m2) gathered via cardiac MRI

Cardiopulmonary Flow (mL/beat)1 hour

Modeling framework will be validated using cardiopulmonary flow (mL/beat) gathered via cardiac MRI

Mean Pressure (mmHg)2 hours

Modeling framework will be validated using pressures (mmHg) gathered via cardiac catheterization

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

Nationwide Children's Hospital

🇺🇸

Columbus, Ohio, United States

Mott Children's Hospital University of Michigan

🇺🇸

Ann Arbor, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath